首页 | 官方网站   微博 | 高级检索  
     

含左氧氟沙星及卷曲霉素方案治疗耐多药肺结核近期疗效分析
引用本文:陈启亮,陈亮,尹建军.含左氧氟沙星及卷曲霉素方案治疗耐多药肺结核近期疗效分析[J].中华结核和呼吸杂志,2003,26(8):454-457.
作者姓名:陈启亮  陈亮  尹建军
作者单位:510630,广州,广东省结核病防治研究所
摘    要:目的 观察和评价含左氧氟沙星和卷曲霉素联合化疗方案在耐多药肺结核 (MDR PTB)治疗中的疗效。方法 将 177例MDR PTB患者分为治疗组 88例和对照组 89例。化疗方案 :治疗组以左氧氟沙星和卷曲霉素为主 ,联合利福喷汀、异烟肼、对氨基水杨酸钠、吡嗪酰胺 ;对照组用链霉素、乙胺丁醇 ,联用药物同治疗组 ,疗程均为 2 1个月。结果 共有 16 1例患者完成化疗疗程 ,治疗组 82例 ,痰菌阴转率 83% ;对照组 79例 ,痰菌阴转率 5 8% ;痰菌阴转率治疗组明显高于对照组 (P <0 0 1) ;治疗组病灶显效率 5 0 % ,空洞闭合率 6 3% ,治疗组优于对照组 (P <0 0 1) ;治疗组的药物不良反应率为 31% ,对照组为 35 % ,两组比较差异无显著性 (P >0 0 5 )。结论 含左氧氟沙星和卷曲霉素的方案治疗MDR PTB ,有助于痰菌阴转和病变吸收好转 ,药物不良反应低 ,值得在临床上推广应用

关 键 词:左氧氟沙星  卷曲霉素  药物治疗  耐多药肺结核  联合化疗  异烟肼  吡嗪酰胺
修稿时间:2003年1月10日

A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis
CHEN Qi-liang,CHEN Liang,YIN Jian-jun. Guangdong Research Institute for Tuberculosis Control,Guangzhou ,China.A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis[J].Chinese Journal of Tuberculosis and Respiratory Diseases,2003,26(8):454-457.
Authors:CHEN Qi-liang  CHEN Liang  YIN Jian-jun Guangdong Research Institute for Tuberculosis Control  Guangzhou  China
Affiliation:Guangdong Research Institute for Tuberculosis Control, Guangzhou 510630, China.
Abstract:OBJECTIVE: To study the clinical efficacy of a combination therapy with levofloxacin (LVFX), capreomycin (CPM) and other second-line antituberculosis drugs in the treatment of multi-drug resistant pulmonary tuberculosis (MDR-TB). METHODS: 177 patients with MDR-TB were assigned to a study group (88 cases), treated with LVFX, CPM, pyrazinamide (PZA), rifapentine (RFT) and pasiniazid (PSZ); or a control group, treated with streptomycin (SM), ethambutol (EMB), PZA, RFT and PSZ. The course of treatment was 21 months. RESULTS: 82 cases in the study group and 79 cases in the control group completed the treatment. The sputum negative conversion rate in the study group (83%) was significantly higher than that in the control group (58%) (P < 0.01). The radiographic improvement rate was 50% in the study group, significantly higher than that in the control group (28%) (P < 0.01). The closure rate of the lung cavities in the study group (63%) was higher than that in the control group (42%) (P < 0.05). No significant difference was found in side-effects between the two groups (31% in the study group, and 35% in the control group respectively) (P > 0.05). CONCLUSION: The regimen including LEVX, CPM and other second-line anti-TB drugs was effective and safe for patients with MDR-TB.
Keywords:Tuberculosis  pulmonary  Tuberculosis  multidrug-resistant  Drug therapy  Treatment outcome
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号